Human laryngeal cancer cell lines
Hep-2,
TU-212, and M4e, and human tubular epithelial cell line HK2 were purchased from the American Type Culture Collection (Manassas, VA USA). The
Hep-2,
TU-212, and HK2 cells were cultured in
RPMI Medium 1640 (Thermo Fisher, Waltham, MA, USA), and M4e cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Gibco; Thermo Fisher, Waltham, MA, USA) supplemented with 10%
fetal bovine serum (Sigma-Aldrich, St. Louis, MO, USA). Cells were cultured in a 37°C incubator containing 5% CO
2. When growth was in logarithmic phase, cells were seeded onto 96-well plates for further study.
Esculetin was purchased from Sigma-Aldrich (99.99% purity) as 100 mM stock solution, and
cisplatin was also purchased from Sigma-Aldrich. STAT3 inhibitor
C188-9 was purchased from Selleck Chemicals (Houston, TX, USA) and the STAT3 activator
colivelin was purchased from Santa Cruz Biotechnology (Dallas, TX, USA). In an
in vitro study, Esc,
C188-9, and
cisplatin were serially diluted with
RPMI Medium 1640 triple and triple. Final working concentrations were 0.0457, 0.1369, 0.4120, 1.229, 3.700, 11.10, and 33.29 μM and the highest working concentration was 100 μM.
Zhang G., Xu Y, & Zhou H.F. (2019). Esculetin Inhibits Proliferation, Invasion, and Migration of Laryngeal Cancer In Vitro and In Vivo by Inhibiting Janus Kinas (JAK)-Signal Transducer and Activator of Transcription-3 (STAT3) Activation. Medical Science Monitor : International Medical Journal of Experimental and Clinical Research, 25, 7853-7863.